PTX-022
PALV-02
Phase 3 small_molecule active
Quick answer
PTX-022 for Pachyonychia Congenita is a Phase 3 program (small_molecule) at PALVELLA THERAPEUTICS, INC. with 3 ClinicalTrials.gov record(s).
Program details
- Company
- PALVELLA THERAPEUTICS, INC.
- Indication
- Pachyonychia Congenita
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active